13F Holdings
中文EN

ZEOX Zeo ScientifiX, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1557376 · Fiscal year ends 06/30

Financial factors as of 2025-10-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY12.5%
TTM net income YoY-17.3%
TTM EPS YoY-16.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin82.1%
Operating margin-103.6%
Net margin-106.2%
FCF margin-14.3%
EBITDA margin-102.2%

Returns

ROE—
ROA-348.3%
ROIC (approx.)—
Asset turnover3.28x

Leverage & solvency

Liabilities / assets193.2%
Debt / equity—
Current ratio0.33x
Interest coverage-54.96x

Cash quality & payout

Operating cash flow / net income0.13x
Accruals ratio-303.0%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242025-10-31FY20242024-10-31FY20232023-10-31FY20222022-10-31FY20212021-10-31
Income statement
Revenue$5.20M$4.62M$4.56M$6.49M$5.60M
Cost of revenue$931,000$844,000$508,000$753,534$547,881
Gross profit$4.27M$3.78M$4.05M$5.74M$5.05M
R&D expense$100,000$164,000$922,700$791,300$1.12M
SG&A expense$9.65M$9.10M$10.82M$14.58M$17.79M
Operating income-$5.39M-$5.32M-$6.77M-$8.84M-$12.74M
Interest expense$98,000$92,000$431,000$398,260$37,934
Pretax income———-$8.90M-$12.76M
Income tax————$0
Net income-$5.52M-$4.71M-$6.99M-$8.90M-$12.76M
EBITDA-$5.31M-$5.25M-$6.28M-$8.51M-$12.69M
EPS (basic)-0.86-0.74-0.99-1.56-0.01
EPS (diluted)-0.86-0.74-0.99-1.56-0.01
Weighted avg. shares (diluted)6.41M6.34M7.03M5.69M1.06B
Banking
Net interest income————-$37,934
Balance sheet
Cash & equivalents$221,000$657,000$1.76M$3.75M$108,570
Receivables$35,000$194,000$18,000$55,110$104,150
Inventory$423,000$232,000$310,000$248,510$234,827
Current assets$958,000$1.17M$2.20M$4.37M$517,194
PP&E, net$569,000$478,000$573,000$1.68M$1.11M
Total assets$1.53M$1.64M$2.78M$6.20M$1.93M
Current liabilities$2.87M$3.29M$4.01M$4.06M$4.13M
Short-term debt$243,000$680,000$657,000$563,111$140,434
Long-term debt——$68,000——
Total debt——$725,000——
Total liabilities$2.95M$3.30M$4.02M$4.31M$4.60M
Shareholders' equity-$1.42M-$1.65M-$1.24M$1.89M-$2.67M
Net debt——-$1.03M——
Shares outstanding6.75M6.34M7.28M7.40M1.13B
Cash flow statement
Operating cash flow-$718,000-$1.45M-$2.20M-$3.17M-$2.68M
Capital expenditure$23,000—$26,000$824,743$424,742
Free cash flow-$741,000—-$2.22M-$3.99M-$3.11M
Investing cash flow-$23,000-$45,000$615,000-$824,743-$424,742
Financing cash flow$305,000$396,000-$415,000$7.64M$2.62M
Depreciation & amortization$73,000$74,000$486,000$332,508$52,702
Stock-based compensation$4.69M$3.85M$3.21M$3.92M$8.65M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.